Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-02-07
2006-02-07
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S204100, C436S063000, C436S064000, C436S174000, C435S004000, C435S005000, C435S007210, C435S007230, C435S325000, C435S363000, C435S366000, C435S372000, C210S767000, C210S780000, C210S781000, C210S782000, C210S788000
Reexamination Certificate
active
06994858
ABSTRACT:
Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
REFERENCES:
patent: 5840502 (1998-11-01), Van Vlasselaer
patent: 5861159 (1999-01-01), Pardoll et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 2002/0037543 (2002-03-01), Atkins et al.
patent: WO 99/08692 (1999-02-01), None
Freshney, R. Ian. Culture of Animal Cells: A Manual of Basic Technique, second edition, p. 217, 1997.
Nordon and Schindhelm. Ex vivo manipulation of cell subsets for cell therapies. Artificial Organs 20(5): 396-402, May 1996.
Gulati and Acaba. Rationale for purging in autologous stem cell transplantation. Journal of Hermatotherapy 2: 467-471, 1993.
Seth, P., et al., “Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging”,Cancer Research56 (6): 1346-1351 (1996).
Wu, A.G. et al., “Bone marrow purging of neuroblastoma by attenuated multimutated herpes simplex virus”,Proceedings of the American Association for Cancer Research Annual39: 605 (1998).
Wu, A, et al., “Biological purging of breast cancer cells using and attenuated replication-competent herpes simplex virus in human hemotopoietic stem cell transplantation”,Cancer Research61 (7): 3009-3015 (2001).
Armstrong, G.D. et al., “Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes”,Virology138:37: 37-48 (1984).
Bensinger, W.I., “Should we purge?”,Bone Marrow Transplant.21:113-115 (1998).
Bos, J. L., “Ras Oncogenes in Human Cancer: A Review”,Canc. Res.49(17): 4682-4689 (1989).
Chandron and Nibert, “Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new typeof infectious subviron particle”,J. of Virology72(1):467-75 (1998).
Coffey, M.C., et al., “Reovirus therapy of tumors with activated Ras pathway”,Science282: 1332-1334 (1998).
Duggan, P.R., et al., “Predictive factors for long-term engraftment of autologous blood stem cells”,Bone Marrow Transplantation26(12): 1299-1304 (2000).
Gao, J., B. Tombal and J.T. Isaacs, “Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts”,Prostate39(1): 67-70, 1999.
Gentsch, J.R.K. and Pacitti, A.F., “Effect of neuraminidase treatment of cells and effect of soluable glycoproteins of type 3 reovirus attachment to murine L cells”,J. Virol. 56:356: 356-64 (1985).
Neito, Y. and E.J. Shpall, “Autologous stem-cell transplantation for solid tumors in adults”,Hematol. Oncol. Clin. North Am.13(5): 939-968 (1999).
Norman, K. and P. Lee, “Reovirus as a novel oncolytic agent”,J. Clin. Invest.105 (8): 1035-1038 (2000).
Paul R. W. et al., “The alpha-anameric form of sialic acid is the minimal receptor determinant recognized by reovirus”, Virology 172: 382-385 (1989).
Spyridonidis, A. et al., “Minimal residual disease in autologous hematopoietic harvests from breast cancer patients”,Annals of Oncology9:821-826 (1998).
Stewart, D.A., et al., “Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens”,Bone Marrow Transplant. 23(2): 111-117 (1999).
Strong, J.E., “The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus”,EMBO J.: 17: 3351-3362 (1998).
Strong, J.E. and P.W. Lee, “The v-erb V oncogene confers enhanced cellular susceptibility to reovirus infection”,J. Virol.70: 612-616 (1996).
Strong, J.E., et al., “Evidence that the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency”,Virology197(1): 405-411 (1993).
Winter, J.N., “High-dose therapy with stem-cell transplantation in the malignant lymphomas”,Oncology(Huntingt) 13(12): 1635-1645 (1999).
Hirai, M., et al. (1999). Adenovirus p53 Purging for Human Breast Cancer Stem Cell Products. Acta Haematol 101(2):97-105.
Coffey Matthew C.
Morris Donald
Thompson Bradley G.
Fish & Richardson P.C.
Harris Alana M.
Oncolytics Biotech Inc.
LandOfFree
Reovirus clearance of ras-mediated neoplastic cells from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus clearance of ras-mediated neoplastic cells from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus clearance of ras-mediated neoplastic cells from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711684